Tumor tissue levels of Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and outcome following adjuvant chemotherapy in premenopausal lymph node-positive breast cancer patients: A retrospective study

BMC Cancer

Volumn 9, Issue , 2009, Pages 322-

  Schrohl, Anne Sofie ^a   Look, Maxime P ^b   Meijer van Gelder, Marion E ^b   Foekens, John A ^b   Brünner, Nils ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; METHOTREXATE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOSENSITIVITY; COHORT ANALYSIS; CONTROLLED STUDY; CYTOSOLIC FRACTION; DISEASE FREE SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PREMENOPAUSE; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; SURVIVAL TIME; TISSUE LEVEL; TREATMENT RESPONSE;

ADULT; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; CYCLOPHOSPHAMIDE; FLUOROURACIL; HUMANS; LYMPHATIC METASTASIS; METHOTREXATE; MIDDLE AGED; PREMENOPAUSE; RETROSPECTIVE STUDIES; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TREATMENT OUTCOME;

EID: 70449449502     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-322     Document Type: Article

References (27)

1. Moulder S, Hortobagyi GN. Advances in the treatment of breast cancer. Clin Pharmacol Ther 2008, 83:26-36. 10.1038/sj.clpt.6100449, 18091763.
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717. 10.1016/S0140-6736(05)66544-0, 15894097.
3. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007, 25:5287-5312. 10.1200/JCO.2007.14.2364, 17954709.
4. Chirco R, Liu XW, Jung KK, Kim HR. Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev 2006, 25:99-113. 10.1007/s10555-006-7893-x, 16680576.
5. Jiang Y, Goldberg ID, Shi YE. Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 2002, 21:2245-2252. 10.1038/sj.onc.1205291, 11948407.
6. Schrohl AS, Meijer-van Gelder ME, Holten-Andersen MN, Christensen IJ, Look MP, Mouridsen HT, Brunner N, Foekens JA. Primary tumor levels of tissue inhibitor of metalloproteinases-1 are predictive of resistance to chemotherapy in patients with metastatic breast cancer. Clin Cancer Res 2006, 12:7054-7058. 10.1158/1078-0432.CCR-06-0950, 17114213.
7. Willemoe GL, Hertel PB, Bartels A, Jensen MB, Balslev E, Rasmussen BB, Mouridsen H, Ejlertsen B, Brunner N. Lack of TIMP-1 tumour cell immunoreactivity predicts effect of adjuvant anthracycline-based chemotherapy in patients (n = 647) with primary breast cancer. A Danish Breast Cancer Cooperative Group Study. Eur J Cancer 2009, 45(14):2528-36. 10.1016/j.ejca.2009.05.029, 19535243.
8. Ejlertsen B, Jensen MB, Nielsen KV, Balslev E, Willemoe GL, Hertel PB, Knoop A, Mouridsen H, Brünner N. TOP2A, TIMP-1 and responsiveness to adjuvant anthracycline containing chemotherapy in high risk breast cancer patients (Abstract). Cancer Res 2009, 69(Suppl):72s.
9. Lipton A, Ali SM, Leitzel K, Demers L, Evans DB, Hamer P, Brown-Shimer S, Pierce K, Carney W. Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancer. Cancer 2007, 109:1933-1939. 10.1002/cncr.22637, 17407159.
10. Lipton A, Leitzel K, Chaudri-Ross HA, Evans DB, Ali SM, Demers L, Hamer P, Brown-Shimer S, Pierce K, Gaur V. Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer. J Clin Oncol 2008, 26:2653-2658. 10.1200/JCO.2007.15.4336, 18443351.
11. Schrohl AS, Christensen IJ, Pedersen AN, Jensen V, Mouridsen H, Murphy G, Foekens JA, Brunner N, Holten-Andersen MN. Tumor Tissue Concentrations of the Proteinase Inhibitors Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and Plasminogen Activator Inhibitor Type 1 (PAI-1) Are Complementary in Determining Prognosis in Primary Breast Cancer. Mol Cell Proteomics 2003, 2:164-172. 10.1074/mcp.M300019-MCP200, 12672830.
12. Wu ZS, Wu Q, Yang JH, Wang HQ, Ding XD, Yang F, Xu XC. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int J Cancer 2008, 122:2050-2056. 10.1002/ijc.23337, 18172859.
13. McCarthy K, Maguire T, McGreal G, McDermott E, O'Higgins N, Duffy MJ. High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer. Int J Cancer 1999, 84:44-48. 10.1002/(SICI)1097-0215(19990219)84:1<44::AID-IJC9>3.0.CO;2-P, 9988231.
14. Schrohl AS, Holten-Andersen MN, Peters HA, Look MP, Meijer-van Gelder ME, Klijn JG, Brunner N, Foekens JA. Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer. Clin Cancer Res 2004, 10:2289-2298. 10.1158/1078-0432.CCR-03-0360, 15073104.
15. Talvensaari-Mattila A, Turpeenniemi-Hujanen T. High preoperative serum TIMP-1 is a prognostic indicator for survival in breast carcinoma. Breast Cancer Res Treat 2005, 89:29-34. 10.1007/s10549-004-1006-8, 15666194.
16. Kuvaja P, Talvensaari-Mattila A, Turpeenniemi-Hujanen T. High preoperative plasma TIMP-1 is prognostic for early relapse in primary breast carcinoma. Int J Cancer 2008, 123:846-851. 10.1002/ijc.23531, 18506691.
17. Wurtz SO, Moller S, Mouridsen H, Hertel PB, Friis E, Brunner N. Plasma and Serum Levels of Tissue Inhibitor of Metalloproteinases-1 Are Associated with Prognosis in Node-negative Breast Cancer: A Prospective Study. Mol Cell Proteomics 2008, 7:424-430.
18. Foekens JA, Look MP, Bolt-de Vries J, Meijer-van Gelder ME, van Putten WL, Klijn JG. Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients. Br J Cancer 1999, 79:300-307. 10.1038/sj.bjc.6690048, 2362199, 9888472.
19. Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brunner N, Janicke F, Meijer-van Gelder ME, Henzen-Logmans SC. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 2000, 60:636-643.
20. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005, 97:1180-1184.
21. Code of Conduct of the Dutch federation of Medical Scientific Societies. , http://www.federa.org
22. EORTC Breast Cancer Cooperative Group Revisions of the standard for the assessment of hormone receptors in human breast cancer. Eur J Cancer 1980, 16:1513-1515.
23. Holten-Andersen MN, Murphy G, Nielsen HJ, Pedersen AN, Christensen IJ, Hoyer-Hansen G, Brunner N, Stephens RW. Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer. Br J Cancer 1999, 80:495-503. 10.1038/sj.bjc.6690384, 2362309, 10408859.
24. Foekens JA, Portengen H, van Putten WL, Peters HA, Krijnen HL, Alexieva-Figusch J, Klijn JG. Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols. Cancer Res 1989, 49:5823-5828.
25. Altman DG. Practical Statistics for Medical Research 1991, London: Chapman & Hall.
26. Davidsen ML, Wurtz SO, Romer MU, Sorensen NM, Johansen SK, Christensen IJ, Larsen JK, Offenberg H, Brunner N, Lademann U. TIMP-1 gene deficiency increases tumour cell sensitivity to chemotherapy-induced apoptosis. Br J Cancer 2006, 95:1114-1120. 10.1038/sj.bjc.6603378, 2360707, 17047657.
27. Wurtz SO, Schrohl A, Brünner N, Lademann U. Tissue inhibitor of metalloproteinases-1 protects the human breast carcinoma cell line MCF-7 S1 against anthracycline-induced cell death by activation of the akt survival pathway [abstract]. Cancer Res 2009, 69(Suppl):161s.